BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims

Reuters04-08
BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims

** Shares of biotech firm BioXcel Therapeutics BTAI.O rise 11.9% to $1.22 premarket

** Co says it has begun enrolling patients in a trial of BXCL501 for acute stress reactions, a short‑term mental health condition that can include anxiety, sleep trouble and pain after traumatic events

** Says the drug is being tested in 100 people soon after incidents such as car crashes, with the goal of calming stress symptoms and preventing longer‑term mental health problems

** Adds the study is led by the University of North Carolina at Chapel Hill and is funded by the U.S. government, while BioXcel supplies the drug

** Says there are currently no recommended medicines for acute stress reactions, and positive results could support use of drugs in urgent cases

** As of last close, stock down ~32% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment